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Abstract
The over-expression of six-transmembrane epithelial antigen of the prostate 1 (STEAP1) underlies the pathogenesis of a
large subset of human cancers. Expressed on the cancer cell surface, STEAP1 is an attractive target for antibody-based
therapy or immunotherapy. However, its role in modulating the pathophysiology of colorectal cancer (CRC) remains
relatively unexplored. In this study, we first demonstrated that the STEAP1 transcript level was significantly higher in CRC
tissues than in normal colonic tissues. Of note, STEAP1 expression negatively correlated with overall survival as determined
from a publicly accessible gene expression profile data set. A loss-of-function approach in cultured CRC cell lines revealed
that STEAP1 silencing suppressed cell growth and increased reactive oxygen species (ROS) production, followed by
apoptosis, through an intrinsic pathway. Mechanistically, the inhibition of STEAP1 was associated with decreased
expression of antioxidant molecules regulated by the transcription factor, nuclear erythroid 2-related factor (NRF2), in CRC
cells. Taken together, we identified high STEAP1 transcript levels leading to reduced ROS production that prevented
apoptosis via the NRF2 pathway in CRC cells as a pathological mechanism in CRC. This study highlights the STEAP1–
NRF2 axis as a therapeutic target for CRC and its manipulation as a novel strategy to conquer CRC.
Introduction
Colorectal cancer (CRC) makes up the fourth largest con-
tribution to cancer-related mortality worldwide, accounting
for around 1.3 million new patients and 700,000 deaths
each year [1]. Although several combination chemotherapy
regimens with cytotoxic drugs and molecular-targeted
agents have led to improved overall survival of patients
with CRC, a low 5-year survival rate for metastatic CRC
highlights the need to develop novel treatment strategies [2,
3]. Reactive oxygen species (ROS), a group of quite reac-
tive ions and molecules, are byproducts of a wide variety of
cellular metabolic reactions [4]. ROS act as oncogenic
signal transducers at low to moderate levels to activate cell
proliferation, migration/invasion, and angiogenesis [5].
Conversely, a highly elevated ROS level can induce several
types of cell death, such as apoptosis, autophagy, and
necrosis [6]. We previously reported that manipulating ROS
production may be used as a therapeutic intervention for
multiple myeloma [7, 8]. As such, disrupting the equili-
brium of cellular oxidative stress is an attractive tool for
cancer treatment in CRC [9]. Therefore, understanding how
CRC cells regulate conditions for ROS is critical to devel-
oping novel strategies to combat CRC. Six-transmembrane
epithelial antigen of the prostate 1 (STEAP1), identified in
prostate cancer (PC) cells as a cell surface protein that is
suggested to work as an intracellular transporter, is over-
expressed in a subset of human cancers, including CRC
[10–12]. Regarding PC, STEAP1 may be useful as a
negative prognostic marker, and shows oncogenic proper-
ties such as the ability to stimulate cell growth [13–15]. In
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cases of Ewing sarcoma (EWS), STEAP1 augmented cell
proliferation and invasion and was accompanied by
increased ROS levels, although how STEAP1 induced ROS
production has not been elucidated [16]. The transcription
factor, nuclear erythroid 2-related factor (NRF2), is a
pivotal regulator of antioxidant responses in both normal
and cancerous cells [17]. Growing evidence suggests that
NRF2 has two contradictory effects in cancer [18]. Basi-
cally, NRF2 is regarded as a tumor suppressor since it can
protect cells from multiple insults, including oxidative
stress, and has cancer chemopreventive capabilities [19].
The other function is as an oncogene because NRF2 is
activated and over-expressed in cancer and promotes cancer
cell survival [20]. The expression and activity of NRF2 is
tightly regulated by numerous molecules, including kelch-
like ECH-associated protein 1 (KEAP1), at transcriptional
and post-transcriptional levels [21]. However, a relationship
between NRF2 and STEAP1 has not been described, and
the biological functions of STEAP1 in cancer remain
undefined. Here, we characterized the biological impact of
STEAP1 in CRC pathogenesis. We showed that STEAP1
transcript levels were over-expressed in CRC compared to
normal cells using three public independent data sets. Over-
expression of STEAP1 was associated with poor prognosis
in patients with CRC. The knock-down of STEAP1 induced
apoptosis by targeting NRF2 suppression, followed by the
inhibition NRF2-targeted genes that activated
antioxidant reactions, leading to the overproduction of
intracellular ROS. Our data provides a rationale for a new
treatment strategy inhibiting the STEAP1–NRF2 pathway
in CRC.
Materials and methods
Databases and gene expression data analysis
Gene expression levels of STEAP1 in normal and can-
cerous tissues were evaluated using the publicly acces-
sible data set (GSE25070, GSE21510, and GSE37364)
from the Gene Expression Omnibus. The correlation
between STEAP1 messenger RNA (mRNA) levels and
clinical outcome was investigated using the publicly
accessible data set (GSE17538) from the Gene Expression
Omnibus. We used receiver operating characteristic
(ROC) curve to determine the cutoff value. In total, 232
patients were categorized as having high or low levels of
STEAP1, and Kaplan–Meier analysis of overall survival
comparing the two groups was performed. Pearson’s
correlation coefficient between STEAP1 and NRF2 in
samples of patients with CRC was analyzed using pub-
licly accessible gene expression profiling data, GSE25070
and GSE21510.
Cell lines and culture conditions
All CRC cell lines were purchased from the American Type
Culture Collection (Manassas, VA, USA). DLD-1, HCT-
116, and SW480 cell lines were cultured in RPMI 1640
(Sigma–Aldrich, St. Louis, MO, USA) containing 10% fetal
bovine serum (FBS), 2 μM L-glutamine and 1% penicillin–
streptomycin. CCD 841 CoTr, Lovo, and LS180 cell lines
were cultured in Dulbecco's Modified Eagle Med-
ium (Sigma–Aldrich) containing 10% fetal bovine serum
(FBS), 2 μM L-glutamine and 1% penicillin–streptomycin.
Cell lines were authenticated by short tandem repeat DNA
profiling in 2018.
Inhibition of STEAP1 expression by small-interfering
RNA
Non-targeting control small-interfering (siRNA; Control;
#4390843, Thermo Fisher Scientific, Waltham, MA, USA)
and two independent siRNAs targeting human STEAP1
(siSTEAP1; MQ-003713-01 and MQ-003713-02, Dharma-
con, Lafayette, CO, USA) were transfected into cell lines
using Lipofectamine RNAiMAX (Thermo Fisher Scientific)
according to the manufacturer’s protocol.
Quantitative reverse transcription-PCR
RNA was extracted with TRIzol Reagent (Thermo Fisher
Scientific) according to the manufacturer’s protocol. Total
RNA (1 μg) was reverse-transcribed using a SuperScript
VILO cDNA synthesis kit (Thermo Fisher Scientific), and
quantitative reverse transcription-PCR (qRT-PCR) was
performed with an Applied Biosystems 7300 Real-time
PCR system (Applied Biosystems, Foster City, CA, USA).
The analysis of target genes was conducted in quadruplicate
using a POWER SYBR Green Master Mix (Thermo Fisher
Scientific) as previously described [22]. Transcripts levels
were normalized to β-actin expression. PCR primer sets for
targeted genes are listed in Supplementary Table.
Western blot
Cells were solubilized in radioimmunoprecipitation assay
(RIPA) lysis buffer (50 mM Tris-HCI, pH 7.5, 1% NP-40,
0.5% Na-deoxycholate, 1mM EDTA, 150mM NaCl, 1mM
EGTA, and protease inhibitor cocktail), and then cen-
trifuged at 12,000 × g for 10 min. The supernatants were
collected, and protein concentrations were determined using
a bicinchoninic acid (BCA) Protein Assay Kit (Thermo
Fisher Scientific). Equal amounts of protein were run on 4–
20% sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS–PAGE) gels and transferred to poly-
vinylidene fluoride (PVDF) membranes (Millipore Corp.,
H. Nakamura et al.
Billerica, MA, USA). The blots were probed using the
following primary antibodies: anti-STEAP1 (sc25514;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
NRF2 (ab62352; abcam, Cambridge, MA, USA), and anti-
actin-horse radish peroxidase (HRP; sc1615; Santa Cruz
Biotechnology).
Evaluation of cell growth
Cells were seeded at densities of 2 × 103 (DLD-1), 1 × 104
(SW480), and 5 × 103 (LS180) cells/well into 96-well
plates. Non-targeting siRNA and two independent siRNAs
targeting human STEAP1 were transfected 24 h later. Cell
viability was assessed at 0, 24, 48, and 72 h using a WST-1
assay (Premix WST-1 Cell Proliferation Assay; Takara Bio,
Otsu, Japan) and an Infinite M1000 PRO microplate reader
(Tecan Japan, Kawasaki, Japan). A growth curve was
constructed by plotting absorbance against time.
Flow cytometry analysis
Cells were seeded at densities of 1.5 × 105 (DLD-1), 6 × 105
(SW480), and 3 × 105 (LS180) cells/well into 6-well plates
and cultured for 24 h. Then, non-targeting siRNA and a
siRNA targeting human STEAP1 were transfected into cells,
and these then incubated for 72 h. STEAP1-silenced cells
were pretreated with or without 10mM N-acetyl-cysteine
(NAC) for 12 h.
Apoptosis was quantified using an Annexin V/7-AAD
staining kit (BD Biosciences, San Jose, CA, USA)
according to the manufacturer’s protocol, followed by
analysis on a BD FACS Canto II instrument (BD Bios-
ciences, Tokyo, Japan) with FACSDiva software (BD
Biosciences) as previously described [23].
Levels of caspases 8 and 9 were indirectly evaluated
using a Caspase8 Assay Kit, Green Fluorescence,
CaspaLux8-L1D2 (OncoImmunin Inc, Gaithersburg, MD,
USA) and a Caspase9 Assay Kit, Green Fluorescence,
CaspaLux9-M1D2 (OncoImmunin) in accordance with the
manufacturer’s protocol, followed by flow cytometry.
Measurements of cytosolic ROS were performed with
CellROX Deep Red (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s protocol. Briefly, cells were
stained for 30 min at 37℃. After staining, cells were
washed and suspended in phosphate-buffered saline. For the
quantification of ROS, cells were analyzed with a BD
FACS Canto II instrument (BD Biosciences).
PCR array
For PCR array, total RNA was reverse-transcribed using a
RT² First Strand Kit (QIAGEN, Germantown, MD, USA).
PCR array was performed using a Signal Transduction
Pathway Finder RT² Profiler PCR array (PAHS-014Z;
QIAGEN) according to the manufacturer’s protocol.
Immunofluorescence
Cells were seeded at densities of 1.5 × 105 (DLD-1) and 6 ×
105 (SW480) cells/well into 6-well plates with coverslips on
the bottom. Non-targeting siRNA and a siRNA targeting
human STEAP1 were transfected 24 h later. The culture
medium was removed 72 h after transfection and cells were
fixed with 4% formaldehyde. Immunofluorescence analysis
was performed using an anti-NRF2 primary antibody as
above, followed by anti-rabbit IgG(H+L), F(ab')2 Fragment
(Alexa Fluor® 488 Conjugate; Cell Signaling Technology,
Danvers, MA, USA). Slides were mounted in ProLong
Gold Antifade Reagent with DAPI (Cell Signaling Tech-
nology). The subcellular localization of NRF2 was observed
using a Biozero BZ-8000 fluorescence microscope (KEY-
ENCE Laboratories, Osaka, Japan).
Statistical analysis
The significance of differences was determined by Student
t-test or Mann–Whitney U-test. Statistical significance was
defined as P < 0.05. All statistical analyses were performed
using EZR software [24].
Results
STEAP1 is over-expressed and associated with poor
prognosis in CRC
To explore the hypothesis that STEAP1 may be related to
CRC pathogenesis, we first investigated STEAP1 expression
in patients with CRC using publicly available gene
expression profiling data. STEAP1 transcript levels were
significantly higher in CRC tissues than in normal colonic
tissues (Fig. 1a, b). Moreover, STEAP1 expression in col-
orectal adenoma was higher than in normal colonic tissues,
and lower than in CRC tissues (Fig. 1c). Although statistical
differences between these groups were non-existent, this
data indicates that STEAP1 expression seems to be
increasingly elevated in the process of an adenoma–carci-
noma sequence [25]. We also evaluated STEAP1 expres-
sion in CRC cell lines. STEAP1 mRNA expression was
significantly higher in several common CRC cell lines
compared to the normal colonic epithelial cell line, CCD
841 CoTr, as determined by qRT-PCR studies (Fig. 1d).
Similarly, western blotting showed that STEAP1 protein
levels in CRC cell lines were significantly higher than in
CCD 841 CoTr cells (Fig. 1e). Thus, our data implied that
STEAP1 may have oncogenic functions, as also reported in
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PC cells [15]. To investigate the impact of STEAP1
expression on survival in patients with CRC, we analyzed
publicly gene expression profiling data. STEAP1 transcript
levels were correlated with overall survival, with a statisti-
cally significant negative correlation between STEAP1
levels and overall survival (Fig. 1f).
STEAP1 silencing inhibits proliferation of CRC cell
lines
To examine the impact of STEAP1 on CRC, we conducted
siRNA knock-down of STEAP1 in three CRC cell lines,
DLD-1 (mutant p53), SW480 (mutant p53), and LS180
(wild-type p53). Knock-down efficiency was examined by
qRT-PCR and western blot. STEAP1 expression in all cell
lines was significantly downregulated by two independent
siRNAs (Fig. 2a, b, d, e, g, h). Next, we tested the influence
of STEAP1 silencing on the proliferation of CRC cell lines
using WST-1 assays. STEAP1 silencing significantly
reduced the proliferation of CRC cell lines for both siRNA
transfectants (Fig. 2c, f, i). Thus, in accordance with loss-of-
function analysis, STEAP1 activated proliferation in CRC
cells regardless of their p53 status.
Knock-down of STEAP1 evokes intrinsic apoptosis in
CRC cell lines
To clarify the mechanism of cytotoxicity induced by
STEAP1 silencing in CRC cell lines, we performed flow
cytometry analysis. Annexin V/7-AAD staining showed an
Fig. 1 STEAP1 expression is upregulated and associated with poor
overall survival in CRC. a, b, c Publicly accessible gene expression
profiling data GSE25070 (a), GSE21510 (b), and GSE37364 (c) were
analyzed to evaluate six-transmembrane epithelial antigen of the
prostate 1 (STEAP1) expression in patients with CRC. *P < 0.05,
***P < 0.001. d Expression of STEAP1 mRNA in colorectal carci-
noma (CRC) cell lines was evaluated by quantitative reverse
transcription (qRT)-PCR. Data are the mean of quadruplicate mea-
surements. Error bars represent the standard deviation. ***P < 0.001. e
Whole-cell lysates from colorectal cancer cell lines were subjected to
immunoblotting using anti-STEAP1 and actin-horse radish peroxidase
(HRP) antibodies. f Correlation between STEAP1 expression and
overall survival in samples of patients with CRC was analyzed using
publicly accessible gene expression profiling data, GSE17538
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increased percentage of apoptosis in STEAP1-silenced CRC
cell lines derived from DLD-1 (Fig. 3a), SW480 (Fig. 3b),
and LS180 (Fig. 3c). A previous report suggested that
STEAP1 accelerated tumor invasiveness via the over-
production of ROS in EWS [16]. To assess the contribution
of ROS in apoptosis, we investigated whether treatment
Fig. 2 STEAP1 silencing leads
to cell growth inhibition in CRC
cell lines. a, b, d, e, g, h Three
different colorectal carcinoma
(CRC) cell lines (DLD-1; a, b,
SW480; d, e, LS180; g, h) were
transfected with non-targeting
siRNA (Control) or two
independent siRNAs targeting
six-transmembrane epithelial
antigen of the prostate 1
(STEAP1; siSTEAP1_1,
siSTEAP1_2). Knock-down
efficiency was evaluated by
quantitative reverse transcription
(qRT)-PCR (a, d, g) and western
blot (b, e, h). Data of qRT-PCR
experiments are the mean of
quadruplicate measurements.
Error bars represent the standard
deviation (SD). **P < 0.01,
***P < 0.001. c, f, i Cell growth
of three different CRC cell lines
(DLD-1; c, SW480; f, LS180; i)
was evaluated using a WST-1
assay at 0, 24, 48, and 96h after
siRNA transfection. Data are the
mean of triplicate
measurements. Error bars
represent the SD. *P < 0.05,
**P < 0.01, ***P < 0.001
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with the ROS scavenger, N-acetyl-cysteine (NAC), might
affect apoptosis. Interestingly, NAC supplementation
markedly decreased the percentage of apoptotic cells in
STEAP1-silenced CRC cell lines. These data strongly
indicated that the apoptosis that followed the knock-down
of STEAP1 was caused by ROS elevation. We next
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examined whether this apoptosis was induced via an
intrinsic or extrinsic pathway using flow cytometry. The
activity of Caspase 8 in STEAP1-silenced DLD-1 cells was
equivalent to that observed in control cells (Fig. 3d). By
contrast, the activity of Caspase 9 was significantly upre-
gulated in STEAP1-silenced DLD-1 cells (Fig. 3e). Fur-
thermore, NAC treatment significantly suppressed Caspase
9 activities induced by STEAP1 knock-down. Collectively,
apoptosis induced by STEAP1 silencing was stimulated in
an ROS-dependent manner and was mediated via an
intrinsic pathway.
Intracellular ROS level is related to STEAP1
expression in CRC cell lines
As shown in Fig. 3a–c, the apoptosis evoked by STEAP1
silencing seems to be associated with ROS. We, therefore,
measured intracellular ROS levels using a flow cytometer to
evaluate whether STEAP1 inhibition stimulated ROS gen-
eration in CRC cell lines. Increased generation of
intracellular ROS was observed in STEAP1-silenced DLD-1
(Fig. 4a), SW480 (Fig. 4b), and LS180 (Fig. 4c) cell lines.
As expected, NAC treatment canceled any increment of
ROS induced by the silencing of STEAP1.
STEAP1 regulates the NRF2-related oxidative stress
response in CRC
To understand the mechanisms involved in increased
intracellular ROS induced by STEAP1 silencing, we ana-
lyzed components of several signal transduction pathways
by PCR array. We found that heme oxygenase 1 (HMOX1),
NAD(P)H quinone dehydrogenase 1 (NQO1), and thior-
edoxin reductase 1 (TXNRD1) transcript expression was
significantly downregulated by STEAP1 silencing (Fig. 5a).
These genes reportedly give rise to NRF2-mediated anti-
oxidant molecules [26]. The mRNA expression levels of
these molecules after STEAP1 silencing were measured by
qRT–PCR. Downregulation of these molecules was
observed when DLD-1 and SW480 cells were transfected
with two independent siRNAs targeting STEAP1 compared
to non-targeting siRNA (Fig. 5b, c). Based on these data,
we hypothesized the existence of a relationship between
STEAP1 and NRF2 expression. Therefore, we evaluated
their expression using publicly accessible gene expression
profiling data, GSE25070 and GSE21510. As expected,
Pearson’s correlation coefficient analysis revealed a sig-
nificant positive relationship between STEAP1 and NRF2
expression in both data sets (Fig. 5d, e). Subsequently, the
expression of NRF2 after STEAP1 silencing in DLD-1 and
SW480 cells was evaluated by qRT-PCR and western blot.
Downregulation of NRF2 was observed in cells when
transfected with two independent siRNAs targeting STEAP1
Fig. 3 Knock-down of STEAP1 induces intrinsic apoptosis in CRC
cell lines. a, b, c DLD-1 (a), SW480 (b), and LS180 (c) cells were
transfected with non-targeting siRNA (Control) or six-transmembrane
epithelial antigen of the prostate 1 (STEAP1) targeting siRNA (siS-
TEAP1) in the absence or presence of N-acetyl-cysteine (NAC) pre-
treatment. Apoptosis was measured by flow cytometry using Annexin
V/7-AAD staining. Data are the mean of triplicate measurements.
Error bars represent the standard deviation (SD). *P < 0.05, **P <
0.01, ***P < 0.001. d, e DLD-1 cells were transfected with non-
targeting siRNA (Control) or STEAP1-targeting siRNA (siSTEAP1) in
the absence or presence of NAC pretreatment. Caspase 8 (d) and
Caspase 9 (e) activities were evaluated by flow cytometry. Data are the
mean of triplicate measurements. Error bars represent the SD. N.S.; not
significant. *P < 0.05. ***P < 0.001
Fig. 4 ROS production is increased by STEAP1 inhibition. a, b, c
DLD-1 (a), SW480 (b), and LS180 (c) cells were transfected with non-
targeting siRNA (Control) or six-transmembrane epithelial antigen of
the prostate 1 (STEAP1) targeting siRNA (siSTEAP1) in the absence
or presence of N-acetyl-cysteine (NAC) pretreatment. Cytosolic
reactive oxygen species (ROS) levels were measured by flow cyto-
metry using CellROX Deep Red. Data are the mean of triplicate
measurements. Error bars represent the standard deviation. *P < 0.05,
**P < 0.01, ***P < 0.001
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compared to non-targeting siRNA (Fig. 5f–i). Furthermore,
we assessed the cellular localization of NRF2 by immuno-
cytochemistry when DLD-1 and SW480 cells were trans-
fected with STEAP1-targeting or non-targeting siRNA
because NRF2 works as a transcription factor to regulate
downstream-targeted genes [20]. The nuclear translocation
of NRF2 was inhibited by STEAP1 silencing (Fig. 5j, k).
Taken together, our data suggest that CRC cells avoid ROS-
dependent apoptosis using a STEAP1–NRF2 pathway
(Supplementary Fig.).
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Discussion
In the current study, we first demonstrated that STEAP1
transcript levels were over-expressed in gene expression
profiling of patients with CRC. These results prompted us
to investigate the biological significance of STEAP1 in
CRC cells using loss-of-function analysis. Our results
from STEAP1 silencing-induced apoptosis implied that
STEAP1 has oncogenic properties in CRC. In fact, the
high expression of STEAP1 was associated with poor
overall survival [12]. Most recently, the knock-down of
STEAP1 suppressed cell growth in PC cells, which are
well documented regarding STEAP1, accompanied by
apoptosis [15]. However, the mechanisms of apoptosis
induced by STEAP1 knock-down in PC cells were not
elucidated. We found that apoptosis induced by STEAP1
silencing in CRC cells was evoked through increased
intracellular ROS levels. In contrast, a previous report
indicated that the knock-down of STEAP1 reduced ROS
production and redox reactions in EWS cells [16].
Although these findings seem inconsistent, numerous
studies have shown that ROS have dual effects in cancer
cells, like a double-edged sword. Namely, ROS promotes
both cell death, including apoptosis, as well as tumor
growth and invasiveness [4]. The fate of cells in response
to ROS may be determined by cellular ROS levels, which
differ among the cancer cell types. As mentioned above,
disrupting the equilibrium of oxidative stress is an
attractive tool for cancer treatment because ROS con-
tribute to tumor aggressiveness while a high amount of
ROS generation can induce apoptosis [9]. Similarly, we
found that the overproduction of ROS triggered apoptosis
in CRC cells. However, a high level of intracellular ROS
is more harmful for normal compared to CRC cells [27].
In the context of translating ROS overproduction to CRC
therapeutics, the targeting of cancer cells is required to
prevent damaging normal cells. In this regard, STEAP1
would be a suitable target for CRC treatment to stimulate
ROS production and induce cancer cell death because
STEAP1 expression is limited in normal tissues [10].
Importantly, we have identified NRF2 as a downstream-
targeted gene of STEAP1 using PCR array, microarray
data sets, qRT-PCR and immunoblot for the first time
(Fig. 5). NRF2 is a master regulator that represses oxi-
dative stress; thus down-regulating NRF2 leads to
increasing intracellular ROS [28]. In the context of our
experimental setting, NRF2 inhibitors may be effective
for CRC treatment. However, NRF2 inhibitors have not
been introduced as a therapeutics in the clinic as yet since
NRF2 has a dual function in both oncogenic and tumor
suppressive activities [18]. Therefore, our results may
prove valuable in developing a STEAP1-driven CRC
treatment to manipulate intracellular NRF2 expression
and therefore ROS production. Collectively, the current
study demonstrated that STEAP1 was over-expressed in
CRC cells compared to normal colonic mucosa and ade-
noma. STEAP1 silencing induced apoptosis in CRC cells
through an overload of ROS due to the suppression of
NRF2-induced antioxidant activities. Our results highlight
the STEAP1–NRF2 axis as a therapeutic target for CRC
and its manipulation as a novel strategy to combat CRC.
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Supplementary Table. Primer sets used for qRT-PCR 
Gene Forward Primer (5' to 3') Reverse Primer (5' to 3') 
β-actin 5’-GGCATCCTCACCCTGAAGTA-3’ 5’-GAAGGTGTGGTGCCAGATTT-3’ 
STEAP1 5’-CCCTTCTACTGGGCACAATACA-3’ 5’-GCATGGCAGGAATAGTATGCTTT-3’ 
HMOX1 5'-TCTCCGATGGGTCCTTACACTC-3' 5'-GGCATAAAGCCCTACAGCAACT-3' 
NQO1 5'-ATGGTCGGCAGAAGAGC-3' 5'-GGAAATGATGGGATTGAAGT-3' 
TXNRD1 5’-CCACTGGTGAAAGACCACGTT-3’ 5’-AGGAGAAAAGATCATCACTGCTGAT-3’ 
NRF2 5’-CACATCCAGTCAGAAACCAGTGG-3’ 5’- GGAATGTCTGCGCCAAAAGCTG -3’ 
STEAP1, six-transmembrane epithelial antigen of the prostate 1; HMOX1, heme oxygenase 
1; NQO1, NAD(P)H quinone dehydrogenase 1; TXNRD1, thioredoxin reductase 1; NRF2, 
nuclear erythroid 2-related factor. 
  
 
Supplementary Figure. Schematic representation of STEAP1–NRF2 pathway 
Under normal conditions, nuclear erythroid 2-related factor (NRF2) is located in the cytoplasm, 
adjacent to kelch-like ECH-associated protein 1 (KEAP1). Oxidative stress causes the 
dissociation of NRF2 from KEAP1. NRF2 enters the nucleus and activates several antioxidant 
genes to mitigate oxidative stress. Our data suggests that Six-transmembrane epithelial 
antigen of the prostate 1 (STEAP1) plays an important role in up-regulating this pathway. 
HMOX1, heme oxygenase 1; NQO1, NAD(P)H quinone dehydrogenase 1; TXNRD1, 
thioredoxin reductase 1, ARE, antioxidant response element. 
 
